Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Critical Review of Cataractogenesis and Lens Contouring in Radiation Oncology.

Advances in radiation oncology·2026

Same author

Ischaemic stroke and 5-fluorouracil or capecitabine: A systematic review and meta-analysis of harms and a retrospective study of the WHO pharmacovigilance database.

British journal of pharmacology·2026

Same author

Multi-omics data integration using time-to event endpoint and supervised Cox penalized regression: a comprehensive review.

Clinical and experimental medicine·2026

Same author

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Oral oncology·2026

Same author

Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Journal for immunotherapy of cancer·2026

Same author

CMV seropositivity associates with poor clinical outcome in triple negative breast cancer.

iScience·2026

Search research articles

Related Experiment Video

Updated: Oct 1, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Nanoparticle therapy for head and neck cancers.

Caroline Hoffmann¹, Colette Shen², Christophe Le Tourneau³

¹Department of Head and Neck Surgery, INSERM U932 Research Unit, Institut Curie, Paris Sciences Lettres (PSL) University, Paris, France.

Current Opinion in Oncology

|March 7, 2022

Summary

This review explores nanoparticle therapies for head and neck cancer (HNC). Advanced nanoparticles are being investigated to improve radiotherapy, deliver chemotherapy, and utilize photothermal therapy for HNC treatment.

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Oct 1, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Published on: November 10, 2023

Area of Science:

Oncology
Nanomedicine
Biotechnology

Background:

Head and neck cancer (HNC) presents significant therapeutic challenges.
Nanoparticles offer novel strategies for targeted cancer treatment.
Current research focuses on advanced nanoparticle applications in HNC therapy.

Purpose of the Study:

To review the therapeutic applications of nanoparticles in head and neck cancer (HNC).
To highlight nanoparticles in advanced clinical development stages for HNC.

Main Methods:

Literature review of nanoparticle-based therapies for HNC.
Analysis of three primary therapeutic approaches: radiotherapy enhancement, targeted drug delivery, and photothermal therapy.
Examination of nanoparticles in various clinical trial phases.

Main Results:

Hafnium oxide nanoparticles are in phase I-III trials for radiotherapy enhancement.
Nanoparticle-mediated delivery of chemotherapy (paclitaxel, cisplatin) and immunotherapy (CpG-A DNA) is under phase II investigation.
No nanoparticle-based therapy is currently FDA-approved for HNC.

Conclusions:

Nanoparticles demonstrate potential across multiple therapeutic modalities for HNC.
Ongoing clinical trials are evaluating the efficacy and safety of various nanoparticle formulations.
Further research and clinical validation are necessary for nanoparticle approval in HNC treatment.